#1 Clinical Trials Search in Europe

Adeno-Associated Viral Vector Serotype 2 Encoding Glial Cell Line-Derived Neurotrophic Factor

This article discusses the clinical trials of AAV2-GDNF, a novel gene therapy treatment for moderate Parkinson’s disease. AAV2-GDNF is an adeno-associated viral vector that delivers the gene for glial cell line-derived neurotrophic factor (GDNF) to the brain. The therapy aims to improve or stabilize motor and non-motor symptoms in patients with moderate Parkinson’s disease. We’ll explore the key aspects of the ongoing clinical trial, including its objectives, eligibility criteria, and potential benefits for patients.

Table of Contents

What is AAV2-GDNF?

AAV2-GDNF is an innovative gene therapy being studied for the treatment of Parkinson’s disease. This therapy uses a special type of virus called adeno-associated virus serotype 2 (AAV2) to deliver a gene that produces a protein called glial cell line-derived neurotrophic factor (GDNF).[1]

The full name of this therapy is “Adeno-Associated Viral Vector Serotype 2 Encoding Glial Cell Line-Derived Neurotrophic Factor.” It’s also known by simpler names like “AAV2-GDNF” or “AB-1005.”[1]

How Does AAV2-GDNF Work?

AAV2-GDNF works by introducing a beneficial gene directly into specific areas of the brain affected by Parkinson’s disease. Here’s a breakdown of how it works:

  1. The therapy is injected into an area of the brain called the putamen, which is involved in movement control.
  2. The AAV2 virus acts as a carrier, delivering the GDNF gene to brain cells.
  3. Once inside the cells, the GDNF gene instructs them to produce the GDNF protein.
  4. GDNF is a protein that helps protect and potentially restore dopamine-producing brain cells, which are damaged in Parkinson’s disease.

By increasing GDNF levels in the brain, researchers hope to slow down or potentially reverse some of the damage caused by Parkinson’s disease.[1]

Clinical Trial Overview

A clinical trial called REGENERATE-PD is currently underway to study the effectiveness and safety of AAV2-GDNF in people with moderate Parkinson’s disease. Here are some key points about the trial:

  • It’s a Phase 2 study, which means it’s testing the therapy in a larger group of people after initial safety studies.
  • The study is randomized, double-blind, and sham surgery-controlled. This means that participants are randomly assigned to either receive the real treatment or a placebo (sham surgery), and neither the patients nor most of the medical staff know who received which.
  • The study will last for 18 months, with various assessments throughout to measure the therapy’s effects.[1]

Eligibility Criteria

To participate in the REGENERATE-PD trial, patients must meet certain criteria. Here are some of the main requirements:

Inclusion Criteria:

  • Adults aged 45-75 years
  • Diagnosed with Parkinson’s disease in the past 4 to 10 years
  • Have moderate disease severity (Hoehn and Yahr stage II-III when not on medication)
  • Show a response to levodopa (a common Parkinson’s medication)[1]

Exclusion Criteria:

  • Other medical conditions that might explain symptoms besides Parkinson’s disease
  • Significant heart or blood vessel diseases
  • Significant cognitive impairment or poorly controlled depression/anxiety
  • History of psychosis or impulse control disorder
  • History of most types of cancer
  • Previous brain surgery or certain other treatments for Parkinson’s disease
  • Chronic use of medications that suppress the immune system[1]

Study Objectives

The REGENERATE-PD trial has several goals:

Main Objective:

To see if AAV2-GDNF can improve or stabilize motor symptoms in people with moderate Parkinson’s disease.[1]

Secondary Objectives:

  • To evaluate if AAV2-GDNF can improve or stabilize both motor and non-motor symptoms
  • To assess its effects on functional impairment, quality of life, and overall symptom severity
  • To evaluate the safety and tolerability of AAV2-GDNF[1]

Potential Benefits

If successful, AAV2-GDNF could offer several potential benefits for people with Parkinson’s disease:

  • Improvement in motor symptoms, such as tremor, stiffness, and slow movement
  • Potential stabilization or slowing of disease progression
  • Improvements in non-motor symptoms and overall quality of life
  • Long-lasting effects from a single treatment, as gene therapy can potentially provide ongoing benefits[1]

Safety Considerations

As with any experimental treatment, there are important safety considerations:

  • The trial carefully monitors for any side effects or adverse events.
  • Participants undergo regular safety assessments, including blood tests and neurological exams.
  • The study also checks for any immune responses to the therapy.
  • The treatment involves brain surgery, which carries its own risks that need to be carefully weighed against potential benefits.[1]

It’s important to note that AAV2-GDNF is still in the research phase. While it shows promise, more studies are needed to fully understand its effectiveness and safety for treating Parkinson’s disease.

Aspect Details
Treatment AAV2-GDNF (Adeno-Associated Viral Vector Serotype 2 Encoding Glial Cell Line-Derived Neurotrophic Factor)
Condition Moderate Parkinson’s Disease
Trial Phase Phase 2
Study Design Randomized, Double-blind, Sham Surgery-controlled
Primary Objective Evaluate efficacy in improving or stabilizing motor symptoms
Key Eligibility Adults 45-75 years, diagnosed with PD for 4-10 years, Hoehn and Yahr stage II-III
Primary Endpoint Change in normalized Good ON time from Baseline to Month 18
Administration Intraputaminal injection
Safety Monitoring Adverse events, laboratory assessments, neurological exams, immune responses

FAQ

  • What is AAV2-GDNF and how does it work? AAV2-GDNF is a gene therapy that uses a harmless virus (AAV2) to deliver the gene for glial cell line-derived neurotrophic factor (GDNF) to the brain. GDNF is a protein that can help protect and restore brain cells affected by Parkinson's disease. The therapy is injected directly into a part of the brain called the putamen, which is involved in movement control.
  • Who is eligible for the AAV2-GDNF clinical trial? The trial is open to adults aged 45-75 who have been diagnosed with Parkinson's disease in the past 4 to 10 years. Participants must have moderate symptoms (Hoehn and Yahr stage II-III) and respond to levodopa treatment. Some exclusion criteria include significant cognitive impairment, history of brain surgery, and certain other medical conditions.
  • What are the main goals of the AAV2-GDNF clinical trial? The primary goal is to evaluate if AAV2-GDNF can improve or stabilize motor symptoms in people with moderate Parkinson's disease. Secondary goals include assessing its effects on non-motor symptoms, quality of life, and overall symptom severity. The trial also aims to evaluate the safety and tolerability of the treatment.
  • How is the effectiveness of AAV2-GDNF measured in the trial? The main measure is the change in 'Good ON time' (when symptoms are well-controlled) over 18 months. Other measures include changes in motor function scores, non-motor symptoms, quality of life, and the proportion of patients showing any improvement. The trial also tracks safety by monitoring side effects and immune responses to the treatment.
  • What makes this trial unique compared to other Parkinson's disease treatments? This trial tests a gene therapy approach, which is different from traditional medication-based treatments. It aims to deliver a therapeutic gene directly to the affected brain area, potentially offering long-term benefits with a single treatment. The trial is also designed as a randomized, double-blind, sham surgery-controlled study, which helps ensure reliable results.

Ongoing Clinical Trials on Adeno-Associated Viral Vector Serotype 2 Encoding Glial Cell Line-Derived Neurotrophic Factor

  • A study to optimize the delivery of AAV2-GDNF and gadoteridol into the brain for patients with Parkinson’s disease

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Long-term safety and effectiveness follow-up study of AB-1005 gene therapy in patients with Parkinson’s disease or multiple system atrophy

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

Glossary

  • AAV2-GDNF: A gene therapy treatment that uses an adeno-associated virus (AAV2) to deliver the gene for glial cell line-derived neurotrophic factor (GDNF) to the brain, aiming to improve symptoms of Parkinson's disease.
  • Parkinson's Disease: A progressive nervous system disorder that affects movement, often causing tremors, stiffness, and difficulty with balance and coordination.
  • Gene Therapy: A technique that uses genes to treat or prevent disease, often by replacing a faulty gene or introducing a new gene to help fight a disease.
  • Putamen: A round structure in the brain that is part of the basal ganglia, involved in regulating movement and affected in Parkinson's disease.
  • Levodopa: A medication commonly used to treat Parkinson's disease symptoms by increasing dopamine levels in the brain.
  • Hoehn and Yahr Scale: A system used to describe how symptoms of Parkinson's disease progress, ranging from stage I (mild symptoms) to stage V (severe symptoms).
  • MDS-UPDRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale, a comprehensive assessment tool used to evaluate the severity of Parkinson's disease symptoms.
  • ON Time: Periods when Parkinson's disease symptoms are well-controlled by medication.
  • OFF Time: Periods when Parkinson's disease symptoms return as medication wears off.
  • Double-blind Study: A research design where neither the participants nor the researchers directly involved know who is receiving the treatment and who is receiving a placebo or control.
  • Sham Surgery: A placebo surgical procedure that mimics the real surgery but without performing the key therapeutic element, used as a control in clinical trials.

References

  1. http://clinicaltrials.eu/trial/study-of-aav2-gdnf-for-adults-with-moderate-parkinsons-disease-using-a-drug-combination/